Lv1
60 积分 2024-08-13 加入
Abstract IA012: REGN10597: A PD-1-targeted, receptor-masked wild type IL-2 with improved therapeutic window for cancer immunotherapy
1天前
求助中
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
6天前
已完结
NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial
6天前
已关闭
Next steps for targeted protein degradation
7天前
已完结
10.1177/02698811211073759
26天前
已完结
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
1个月前
已完结
MicroRNA-212-3p regulates early neurogenesis through the AKT/mTOR pathway by targeting MeCP2
1个月前
已关闭
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism
2个月前
已完结
P2Y12 Receptor Inhibitor for Antiaggregant Therapies: From Molecular Pathway to Clinical Application
2个月前
已关闭
Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12receptor antagonist
2个月前
已完结
皖公网安备34019202002308
